Filing Date Form TypeDescription   
   
Data pager
 Page 1 of 11, items 1 to 13 of 142.
2020-02-14SC 13D/A[Amend] General statement of acquisition of beneficial ownershipAcc-no: 0001213900-20-003974 (34 Act)  Size: 67 KB
2020-02-14SC 13D/A[Amend] General statement of acquisition of beneficial ownershipAcc-no: 0001213900-20-003973 (34 Act)  Size: 44 KB
2020-02-14SC 13D/A[Amend] General statement of acquisition of beneficial ownershipAcc-no: 0001213900-20-003972 (34 Act)  Size: 43 KB
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualsAcc-no: 0001104659-20-021049 (34 Act)  Size: 90 KB
2020-02-108-KCurrent report, items 1.01, 7.01, and 9.01 Acc-no: 0001213900-20-003050 (34 Act)  Size: 475 KB
2020-01-294Statement of changes in beneficial ownership of securitiesAcc-no: 0001104659-20-008253 Size: 5 KB
2020-01-278-KCurrent report, items 1.01 and 9.01 Acc-no: 0001213900-20-001935 (34 Act)  Size: 54 KB
2020-01-138-KCurrent report, items 7.01 and 9.01 Acc-no: 0001213900-20-000847 (34 Act)  Size: 19 MB
2020-01-093Initial statement of beneficial ownership of securitiesAcc-no: 0001213900-20-000646 Size: 4 KB
2020-01-028-KCurrent report, items 7.01 and 9.01 Acc-no: 0001213900-20-000044 (34 Act)  Size: 29 KB
2019-12-178-KCurrent report, items 7.01 and 9.01 Acc-no: 0001213900-19-026351 (34 Act)  Size: 53 KB
2019-12-038-KCurrent report, items 7.01 and 9.01 Acc-no: 0001213900-19-025204 (34 Act)  Size: 31 KB
2019-11-298-KCurrent report, items 3.02, 5.02, 8.01, and 9.01 Acc-no: 0001213900-19-025038 (34 Act)  Size: 49 KB


INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
2/10/2020 2:08:22 PM

INmune Bio, Inc. (INMB), an immunology company developing treatments that reprogram the patient’s innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS). The endowment was awarded through the Association’s The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years. “We are honored to receive this grant from The ALS Association, the pre-eminent organization supporting novel treatments for ALS,” said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio.

Have Insiders Been Buying INmune Bio Inc. (NASDAQ:INMB) Shares?
1/29/2020 1:25:50 PM

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals
1/2/2020 2:00:10 PM

INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the publication of new positive data in the journal Alzheimer’s Research & Therapy. The data highlights INmune Bio’s lead compound, XPro1595, as a potentially effective therapy to lower the risk for Alzheimer’s disease in obese individuals.

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials
12/17/2019 2:00:10 PM

INmune Bio, Inc., an immunology company developing therapies that reprogram the patient’s innate immune system to treat diseases, today announced that it has successfully completed the Phase I trial of INB03 and the database has been locked. The Phase I trial was an open-label, dose-escalation trial in patients with advanced solid tumors. “This was our first trial of the DN-TNF platform in patients, and we are pleased with the safety and efficacy results,” said RJ Tesi, MD, CEO and CMO of INmune Bio.

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
12/2/2019 2:00:10 PM

LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today the dosing of the first patient in the Phase Ib clinical trial for patients with Alzheimer's disease. The trial is examining the safety and efficacy of INmune Bio’s XPro1595, a next-generation anti-inflammatory drug that selectively neutralizes the “bad” inflammation, soluble tumor necrosis factor (sTNF), which is strongly implicated in Alzheimer's disease.

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar
11/26/2019 11:00:10 AM

INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development. Lawrence T. Friedhoff, M.D., Ph.D., who is credited with the development and commercialization of Aricept, which was FDA approved for the symptomatic treatment of mild to moderate Alzheimer's disease.

INMB: Potential Link Between Obesity and Neuroinflammation Shown in Mouse Model of Alzheimer’s…
11/25/2019 1:05:00 PM

By David Bautz, PhD NASDAQ:INMB READ THE FULL INMB RESEARCH REPORT Business Update Link Between Obesity and Alzheimer’s Presented at Society for Neuroscience Annual Meeting On October 21, 2019, INmune Bio, Inc. (NASDAQ:INMB) announced a presentation at the Society for Neuroscience 49th Annual Meeting showing the company’s lead compound, XPro1595, appears to mitigate Alzheimer’s-like pathology

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen
11/19/2019 2:00:00 PM

LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, today announced that Marcia Allen has joined the company’s board as an independent director. “Marcia is recognized as a leader in the financial community and brings a unique, broad ranging international experience to the Board that further strengthens our team,” said RJ Tesi, MD, INmune Bio’s Chief Executive Officer and Chief Medical Officer.

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update
11/8/2019 9:00:00 PM

LA JOLLA, Calif., Nov. 08, 2019 -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system.

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting
10/21/2019 7:00:05 PM

INmune Bio, Inc. (INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today that Dr. Malú Tansey presented data that show the use of INmune Bio’s lead compound, XPro1595, appear to mitigate the exacerbation of Alzheimer’s-like pathology triggered by a high fat and high fructose diet in mice. Dr. Tansey was the lead speaker at a press conference during the Society for Neuroscience (SfN) 49th Annual Meeting, today in Chicago.

Here's Why We're Not Too Worried About INmune Bio's (NASDAQ:INMB) Cash Burn Situation
10/21/2019 2:42:01 PM

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting
10/17/2019 1:00:05 PM

INmune Bio, Inc. (INMB), an immunotherapy company developing treatments that harness the patient’s innate immune system to fight disease, announced today a poster presentation related to the company’s program in Alzheimer’s disease at the upcoming Society for Neuroscience (SfN) 49th Annual Meeting, to be held Oct. 19–23 at McCormick Place in Chicago. In addition, INmune Bio announced that this presentation has been selected for presentation during the meeting’s press conference.

INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
10/8/2019 1:00:00 PM

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, M.D., Co-Founder and CEO, will present at the 2nd Annual Advances in Immuno-Oncology USA Congress in San Diego taking place on Oct. 8 and Oct. 9. “The immuno-oncology field is rapidly growing, and emerging new therapies are at the center of attention,” said Dr. Tesi.

CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress
9/24/2019 2:20:00 PM

La Jolla, CA., Sept. 24, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. “Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr. Tesi.

INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzheimer’s Association International Conference (AAIC) Satellite Symposium
9/23/2019 1:03:00 PM

INmune Bio, Inc. (INMB), an immunotherapy company developing treatments which harness the patient’s innate immune system to fight disease, announced today that the company will be presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia. C.J. Barnum, Ph.D., Director of Neuroscience at INmune Bio, will present the company’s strategy for treating Alzheimer’s disease at a panel session, along with other global researchers and leaders in the latest therapeutics and developments in Alzheimer’s clinical research.

6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
9/20/2019 2:02:02 PM

Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.

INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
9/17/2019 1:05:00 PM

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will present at the first ever Targeting Innate Immunity Congress, taking place in the biotech hub of Cambridge, Mass. from Sept. 23 through 25. The conference is an opportunity for INmune Bio to showcase its two leading innate compounds in the hopes of improving the treatment of cancer to industry leaders, experts, academic researchers and clinicians in the field of innate immunity. In addition to presenting at the conference, Dr. Tesi and Dr. Lowdell will be instructing a course on the role of the tumor microenvironment (TME) in immunosuppression.

INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer
9/12/2019 12:30:00 PM

INmune Bio, Inc. (INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient’s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR”, which covers INmune’s INB03 Program utilizing dominant negative TNFα (DN-TNFα) technology for treating cancer. “This is an important patent for INmune Bio, Inc. and provides exclusivity for use of our DN-TNFα technology for the treatment of cancer,” said Joshua Schoonover, Assoc.

INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET
9/5/2019 12:33:00 PM

LA JOLLA, Calif., Sept. 05, 2019 -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to.

INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference
9/4/2019 1:06:00 PM

The presentation will be webcast live on September 9 and will remain available for 90 days through the Investor Relations section of INmune Bio’s website. “NASH presents a significant unmet medical need.  We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow the liver to heal,” said RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “NeuLiv precisely targets soluble TNF, a key cytokine driving pathologic chronic inflammation.